400 SPECTRUM CENTER DRIVE, IRVINE, CA
CG Oncology, Inc. Files Amendment No. 1 for $550 Million Common Stock Offering
Investor Presentation
Appointment of Christina Rossi to CG Oncology Board of Directors
Resignation of Robert Lapetina as Principal Financial Officer
Reports Third Quarter 2025 Financial Results and Provides Business Updates
Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months
Reports Second Quarter 2025 Financial Results and Provides Business Updates
Q2
Q1
FY 2024
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
Amended Registration Statement for Securities
S-1
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Initial Statement of Beneficial Ownership
Schedule 13G - Ownership Report